RedHill Biopharma Secures New US Patent for COVID-19 Treatment Biomarker Valid Through 2041
Portfolio Pulse from Benzinga Newsdesk
RedHill Biopharma Ltd. (NASDAQ:RDHL) has secured a new U.S. patent for a COVID-19 treatment biomarker, valid through 2041. The patent is based on data showing opaganib's efficacy in treating COVID-19, including reduced mortality and improved patient outcomes. Opaganib is a broad-acting drug with potential applications in various diseases.
September 30, 2024 | 11:03 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
RedHill Biopharma has obtained a new U.S. patent for a COVID-19 treatment biomarker, enhancing its opaganib drug's market potential. The patent supports opaganib's efficacy in reducing COVID-19 mortality and improving patient outcomes.
The new patent strengthens RedHill's intellectual property portfolio and supports the efficacy of opaganib in treating COVID-19, which could lead to increased market interest and potential partnerships or funding opportunities.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100